BioLineRx (BLRX) Q1 2025 earnings summary

Executive summary

• Outlicensed Effexta/APHEXDA to Aramid/Ayrmid, covering all indications except solid tumors and Asia, with upfront payment, milestones, and royalties, and shifted focus to evaluating new oncology and rare disease assets, expecting a meaningful transaction in 2025.

• Effexta/APHEXDA generated $1.4 million in Q1 2025 sales and $0.3 million in royalty revenue under Aramid/Ayrmid.

• Streamlined operations by shutting down U.S. commercial activities and reducing headcount, lowering annual cash burn by over 70%.

• Motixafortide clinical programs in pancreatic cancer and sickle cell disease progressing, with new data presented at ASCO 2025.

Financial highlights

• Q1 2025 total revenues were $0.3 million, down from $6.9 million in Q1 2024, reflecting transition to royalty-based income.

• Net income for Q1 2025 was $5.1 million, compared to a net loss of $0.7 million in Q1 2024, driven by non-operating income from warrant revaluation.

• Research and development expenses decreased to $1.6 million from $2.5 million year-over-year, due to out-licensing and headcount reduction.

• No sales and marketing expenses in Q1 2025, down from $6.3 million in Q1 2024, following U.S. operations shutdown.

• Cash and equivalents stood at $26.4 million as of March 31, 2025, with a cash runway projected through the second half of 2026.

Outlook and guidance

• Cash runway includes projected development costs for new assets, offset by expected milestones and royalties.

• Anticipates making a definitive announcement on new asset in-licensing later in 2025.

• Full enrollment for the CheMo4METPANC Phase 2b trial targeted for 2027, with interim analysis at 40% PFS events.

• Expects continued royalty and milestone revenue from Aramid and Gloria agreements, with Effexta market opportunity estimated at $100 million+ annually.